2. Apoptosis NF-κB Metabolic Enzyme/Protease Immunology/Inflammation
  3. Ferroptosis Reactive Oxygen Species (ROS)
  4. Ferroptosis-IN-26

Ferroptosis-IN-26 is a CEPT1-targeting ferroptosis inhibitor. Ferroptosis-IN-26 enhances CEPT1-dependent phosphatidylcholine remodeling to enrich cellular membranes with monounsaturated fatty acid-containing phosphatidylcholine (PC-MUFA). Ferroptosis-IN-26 suppresses lipid peroxidation. Ferroptosis-IN-26 can be used for the research of acute liver injury.

For research use only. We do not sell to patients.

Ferroptosis-IN-26

Ferroptosis-IN-26 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Ferroptosis-IN-26 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ferroptosis-IN-26 is a CEPT1-targeting ferroptosis inhibitor. Ferroptosis-IN-26 enhances CEPT1-dependent phosphatidylcholine remodeling to enrich cellular membranes with monounsaturated fatty acid-containing phosphatidylcholine (PC-MUFA). Ferroptosis-IN-26 suppresses lipid peroxidation. Ferroptosis-IN-26 can be used for the research of acute liver injury[1].

In Vitro

Ferroptosis-IN-26 (Compound 4g) potently inhibits RSL3 (HY-100218A)-induced ferroptosis in 786-O cells with an EC50 of 0.16 μM[1].
Ferroptosis-IN-26 potently inhibits RSL3-induced ferroptosis in HT-1080 cells with an EC50 of 0.15 μM[1].
Ferroptosis-IN-26 potently inhibits RSL3-induced ferroptosis in H9c2 cells with an EC50 of 93 nM[1].
Ferroptosis-IN-26 potently inhibits RSL3-induced ferroptosis in SK-HEP-1 cells with an EC50 of 102 nM[1].
Ferroptosis-IN-26 potently inhibits Erastin (HY-15763)-induced ferroptosis in HT-1080 cells with an EC50 of 0.27 μM[1].
Ferroptosis-IN-26 potently inhibits FIN56 (HY-103087)-induced ferroptosis in HT-1080 cells with an EC50 of 0.32 μM[1].
Ferroptosis-IN-26 (1 μM) suppresses RSL3-induced lipid ROS accumulation in 786-O and H9c2 cells[1].
Ferroptosis-IN-26 (1 μM) suppresses Erastin- and FIN56-induced lipid ROS accumulation in HT-1080 cells[1].
Ferroptosis-IN-26 (1 μM; 24 h) does not protect SK-HEP-1 or 786-O cells against STS-induced apoptosis[1].
Ferroptosis-IN-26 (1 μM; 24 h) does not protect SK-HEP-1 or 786-O cells against H2O2-induced necrosis[1].
Ferroptosis-IN-26 (up to 1.5 μM; 24 h) has low inherent cytotoxicity in HEK293T cells, with a CC50 greater than 20 μM[1].
Ferroptosis-IN-26 (1-2 μM; 0-180 min) does not inhibit AAPH (HY-Y0525)-induced lipid peroxidation in EggPC liposomes[1].
Ferroptosis-IN-26 (50 μM) does not exhibit DPPH radical scavenging activity[1].
Ferroptosis-IN-26 does not alter cellular glutathione levels in cells treated with Erastin[1].
Ferroptosis-IN-26 does not alter cellular total free thiol levels in cells treated with Erastin[1].
Ferroptosis-IN-26 (0.5-10 μM) does not alter the expression of ferroptosis-associated proteins in cells[1].
Ferroptosis-IN-26 inhibits RSL3-induced ferroptosis in SK-HEP-1 and 786-O cells independently of the FSP1/CoQ10 system[1].
Ferroptosis-IN-26 inhibits RSL3-induced ferroptosis in GPX4-knockout HT-1080 cells, demonstrating activity independent of GPX4 function[1].
Ferroptosis-IN-26 (3 μM; 72 h) increases cellular levels of MUFA-enriched phosphatidylcholine species in 786-O cells[1].
The antiferroptotic activity of Ferroptosis-IN-26 in SCD1-knockout 786-O and HT-1080 cells is independent of SCD1-mediated MUFA generation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ferroptosis-IN-26 Related Antibodies

Cell Viability Assay[1]

Cell Line: SK-HEP-1 cells; 786-O cells
Concentration: 1 μM
Incubation Time: 24 h
Result: Did not protect SK-HEP-1 or 786-O cells against STS-induced apoptosis.

Cell Viability Assay[1]

Cell Line: SK-HEP-1 cells; 786-O cells
Concentration: 1 μM
Incubation Time: 24 h
Result: Did not protect SK-HEP-1 or 786-O cells against H2O2-induced necrosis.
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUClast AUCINF_obs MRTINF_obs F ClF_obs Vss_obs
Rat[1] 5 mg/kg i.v. 2.718 h / / 2034.418 ng·h/mL 2054.383 ng·h/mL 1.577 h / 40.779 mL/min/kg 3817.128 mL/kg
Rat[1] 10 mg/kg p.o. 4.92 h 1.0 h 75.667 ng/mL 210.351 ng·h/mL 221.607 ng·h/mL 4.973 h 5.2 % / /
In Vivo

Ferroptosis-IN-26 (Compound 4g) (10 mg/kg) protects against hepatic ischemia-reperfusion injury in mice by mitigating ferroptosis-related hepatocellular damage, lipid peroxidation, and iron accumulation[1].
Ferroptosis-IN-26 (5-10 mg/kg) ameliorates ConA (HY-P2149)-induced acute liver injury in mice by suppressing ferroptosis and hepatocellular damage[1].
Ferroptosis-IN-26 (5 mg/kg) ameliorates APAP (HY-66005)-induced acute liver injury in C57 mice by improving liver function and reducing hepatocellular damage[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (male; eight weeks old; intravenously injected with 15 mg/kg ConA to establish an acute liver injury model)[1]
Dosage: 5 mg/kg; 10 mg/kg
Administration: i.p.; 2 doses administered 24 h apart
Result: Significantly alleviated hepatocellular lesions.
Markedly reduced serum levels of the liver injury markers ALT and AST.
Substantially decreased 4-HNE adducts.
Significantly reduced serum MDA levels.
Downregulated the mRNA expression of the ferroptosis-associated gene Ptgs2 in mice livers.
Animal Model: C57BL/6 mice (male; six weeks old; 18-22 g; intraperitoneally injected with 400 mg/kg APAP to establish an acute liver injury model)[1]
Dosage: 5 mg/kg; 10 mg/kg
Administration: i.p.; 2 doses administered 24 h apart
Result: Markedly reduced serum levels of the liver injury markers ALT and AST.
Animal Model: C57BL/6 mice (male; eight weeks old; hepatic ischemia-reperfusion injury)[1]
Dosage: 10 mg/kg
Administration: i.p.; 2 doses at 36 h and again
at 12 h prior to surgery
Result: Markedly ameliorated extensive ischemic areas and inflammatory infiltration.
Significantly attenuated the HIRI-induced elevation in serum ALT and AST levels.
Significantly reduced serum MDA levels.
Molecular Weight

364.40

Formula

C24H16N2O2
SMILES

CC1=CC2=C(C=C1O)OC3=NC4=C(C(C=CC=C5)=C5N4)C(C6=CC=CC=C6)=C32
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ferroptosis-IN-26 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ferroptosis-IN-26FerroptosisReactive Oxygen Species (ROS)murine modelsphosphatidylcholine remodelinghepatic ischemia-reperfusion injuryacute liver injuryHT-1080 cellsmonounsaturated fatty acid-containing phosphatidylcholine786-O cellslipid peroxidationferroptosisCEPT1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ferroptosis-IN-26
Cat. No.:
HY-183589
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.